New agents for the treatment of drug-resistant Mycobacterium tuberculosis.
暂无分享,去创建一个
Richard E. Lee | Daniel T Hoagland | Jiuyu Liu | Robin B Lee | Richard E Lee | Jiuyu Liu | Robin E B Lee | Robin B. Lee | Robin. B. Lee
[1] C. Ehrhardt,et al. Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis. , 2013, Therapeutic delivery.
[2] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[3] Andrew R. Francis,et al. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis , 2009, Proceedings of the National Academy of Sciences.
[4] D. Sherman,et al. Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis , 2013, PloS one.
[5] S. Cole,et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. , 2014, The Lancet. Infectious diseases.
[6] Steven Edward Kern,et al. Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions , 2011, Antimicrobial Agents and Chemotherapy.
[7] Meng Wang,et al. Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase , 2013, Scientific Reports.
[8] F. Blasi,et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use , 2014, European Respiratory Journal.
[9] I. Abubakar,et al. Clinical implications of the global multidrug-resistant tuberculosis epidemic. , 2015, Clinical medicine.
[10] Marisa Klopper,et al. Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa , 2013, Emerging Infectious Diseases.
[11] P. Tonge,et al. Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity. , 2009, ACS chemical biology.
[12] J. Beijnen,et al. Pharmacokinetic interaction between rifampin and zidovudine , 1993, Antimicrobial Agents and Chemotherapy.
[13] Hong Sun,et al. Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases , 2014, Journal of medicinal chemistry.
[14] J. Blanchard,et al. Tebipenem, a New Carbapenem Antibiotic, Is a Slow Substrate That Inhibits the β-Lactamase from Mycobacterium tuberculosis , 2014, Biochemistry.
[15] B. Meibohm,et al. In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics , 2015, Scientific Reports.
[16] H. Matter,et al. Targeting DnaN for tuberculosis therapy using novel griselimycins , 2015, Science.
[17] W. Bishai,et al. Molecular Basis of Drug Resistance in Mycobacterium tuberculosis. , 2014, Microbiology spectrum.
[18] Q. Zeng,et al. Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa , 2015 .
[19] T. Buclin,et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones , 2014, EMBO molecular medicine.
[20] Brendan Prideaux,et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. , 2011, Analytical chemistry.
[21] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[22] D. Schnappinger,et al. Evaluating the Sensitivity of Mycobacterium tuberculosis to Biotin Deprivation Using Regulated Gene Expression , 2011, PLoS pathogens.
[23] Vincent Hernandez,et al. An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site , 2007, Science.
[24] M. Humphries,et al. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. , 1987 .
[25] L. Eckhardt-Strelau,et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline , 2015, Science Advances.
[26] M. Humphries,et al. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. , 1993, The American review of respiratory disease.
[27] J. Palomino,et al. Drug Resistance Mechanisms in Mycobacterium tuberculosis , 2014, Antibiotics.
[28] R. Goldman. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? , 2013, Tuberculosis.
[29] Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and “Anagrams” Generated Potent Antituberculosis Agents , 2014, ACS infectious diseases.
[30] N. Clumeck,et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [Case study]. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[31] Amanda B. Keener. Oldie but goodie: Repurposing penicillin for tuberculosis , 2014, Nature Medicine.
[32] K. Reynolds,et al. Antibacterial targets in fatty acid biosynthesis. , 2007, Current opinion in microbiology.
[33] Eric D Brown,et al. New targets and screening approaches in antimicrobial drug discovery. , 2005, Chemical reviews.
[34] V. Dartois. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells , 2014, Nature Reviews Microbiology.
[35] Giovanni Sotgiu,et al. Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB , 2012, European Respiratory Journal.
[36] J. Nieman,et al. Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria , 2013, Antimicrobial Agents and Chemotherapy.
[37] B. Wolucka,et al. Biosynthesis of D‐arabinose in mycobacteria – a novel bacterial pathway with implications for antimycobacterial therapy , 2008, The FEBS journal.
[38] Peter J. Tonge,et al. A Structural and Energetic Model for the Slow-Onset Inhibition of the Mycobacterium tuberculosis Enoyl-ACP Reductase InhA , 2014, ACS chemical biology.
[39] Dirk Bald,et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. , 2007, Nature chemical biology.
[40] Paul W Smith,et al. Direct inhibitors of InhA are active against Mycobacterium tuberculosis , 2015, Science Translational Medicine.
[41] Jukka Corander,et al. Evolution and transmission of drug resistant tuberculosis in a Russian population , 2014, Nature Genetics.
[42] N. Loman,et al. University of Birmingham Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB , 2012 .
[43] M. Raviglione. XDR-TB: entering the post-antibiotic era? , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[44] Christopher B. Cooper,et al. Lead optimization of 1,4-azaindoles as antimycobacterial agents. , 2014, Journal of medicinal chemistry.
[45] K. Holt,et al. Out-of-Africa migration and Neolithic co-expansion of Mycobacterium tuberculosis with modern humans , 2013, Nature Genetics.
[46] S. Turk,et al. Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis. , 2015, Journal of medicinal chemistry.
[47] A. Crook,et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. , 2014, The New England journal of medicine.
[48] Se Yeon Kim,et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis , 2013, Nature Medicine.
[49] P. Donald,et al. Old and new drugs for the treatment of tuberculosis in children. , 2007, Paediatric respiratory reviews.
[50] M. García-Díaz,et al. Rational Modulation of the Induced-Fit Conformational Change for Slow-Onset Inhibition in Mycobacterium tuberculosis InhA. , 2015, Biochemistry.
[51] G. Riccardi,et al. Trends in discovery of new drugs for tuberculosis therapy , 2014, The Journal of Antibiotics.
[52] Peter J. Tonge,et al. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[53] Per Källblad,et al. Experimental Validation of a Fragment Library for Lead Discovery Using SPR Biosensor Technology , 2011, Journal of biomolecular screening.
[54] J. Davies. Where have All the Antibiotics Gone? , 2006, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[55] H. Noufflard-Guy-Loé,et al. [Experimental antituberculous action of a new antibiotic: RP 11,072]. , 1965, Revue de tuberculose et de pneumologie.
[56] B. Meibohm,et al. Spectinamides: A New Class of Semisynthetic Anti-Tuberculosis Agents that Overcome Native Drug Efflux , 2014, Nature Medicine.
[57] Vijay T. Ahuja,et al. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. , 2013, Journal of medicinal chemistry.
[58] P. Hopewell,et al. Imipenem for Treatment of Tuberculosis in Mice and Humans , 2005, Antimicrobial Agents and Chemotherapy.
[59] Karl-Heinz Altmann,et al. Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA. , 2014, Nature chemical biology.
[60] J. Karlowsky,et al. Faropenem: review of a new oral penem , 2007, Expert review of anti-infective therapy.
[61] R. Parrot,et al. [Rifomycin levels in the lung and tuberculous lesions in man]. , 1969, Acta tuberculosea et pneumologica Belgica.
[62] S. Butler,et al. Bactericidal Activity and Mechanism of Action of AZD5847, a Novel Oxazolidinone for Treatment of Tuberculosis , 2013, Antimicrobial Agents and Chemotherapy.
[63] M. Matsumoto,et al. OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice , 2006, PLoS medicine.
[64] C. Nacy,et al. In Vitro Antimycobacterial Activities of Capuramycin Analogues , 2007, Antimicrobial Agents and Chemotherapy.
[65] Gee Young Suh,et al. Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.
[66] Stewart T. Cole,et al. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.
[67] M. Reed,et al. Contribution of the Mycobacterium tuberculosis MmpL Protein Family to Virulence and Drug Resistance , 2005, Infection and Immunity.
[68] J. Holton,et al. A steric block in translation caused by the antibiotic spectinomycin. , 2007, ACS chemical biology.
[69] Alexander Hillisch,et al. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. , 2006, Drug discovery today.
[70] Uwe Sauer,et al. Fumarate Reductase Activity Maintains an Energized Membrane in Anaerobic Mycobacterium tuberculosis , 2011, PLoS pathogens.
[71] L. Chiarelli,et al. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis , 2013, Applied Microbiology and Biotechnology.
[72] Wonsik Lee,et al. Novel Inhibitors of Cholesterol Degradation in Mycobacterium tuberculosis Reveal How the Bacterium’s Metabolism Is Constrained by the Intracellular Environment , 2015, PLoS pathogens.
[73] S. Schwarz,et al. Mutations in 16S rRNA and Ribosomal Protein S5 Associated with High-Level Spectinomycin Resistance in Pasteurella multocida , 2007, Antimicrobial Agents and Chemotherapy.
[74] R. Bhattacharyya,et al. Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis , 2014, The Journal of Antibiotics.
[75] F. Manetti,et al. New derivatives of BM212: A class of antimycobacterial compounds based on the pyrrole ring as a scaffold. , 2007, Mini reviews in medicinal chemistry.
[76] J. Blanchard,et al. Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis , 2009, Science.
[77] H. S. Schaaf,et al. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. , 2014, Tuberculosis.
[78] K. Dooley,et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? , 2013, The Journal of infectious diseases.
[79] P. Devarajan,et al. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[80] Su Mei Yew,et al. Genome Analysis of the First Extensively Drug-Resistant (XDR) Mycobacterium tuberculosis in Malaysia Provides Insights into the Genetic Basis of Its Biology and Drug Resistance , 2015, PloS one.
[81] S. Cole,et al. Towards a new tuberculosis drug: pyridomycin – nature's isoniazid , 2012, EMBO molecular medicine.
[82] Peter G. Schultz,et al. University of Birmingham Identification of a small molecule with activity against drug-resistant and persistent tuberculosis , 2013 .
[83] B. Barrell,et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.
[84] C. Rock,et al. Inhibiting Bacterial Fatty Acid Synthesis* , 2006, Journal of Biological Chemistry.
[85] J. Mainardi,et al. Inactivation of Mycobacterium tuberculosis l,d-Transpeptidase LdtMt1 by Carbapenems and Cephalosporins , 2012, Antimicrobial Agents and Chemotherapy.
[86] Paul W Smith,et al. Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis , 2013, Science Translational Medicine.
[87] C. Nathan,et al. A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis. , 2015, Methods in molecular biology.
[88] Marco Pieroni,et al. Indoleamides are active against drug-resistant Mycobacterium tuberculosis , 2013, Nature Communications.
[89] B. Terlain,et al. [Structure of griselimycin, polypeptide antibiotic extracted from streptomyces cultures. II. Structure of griselimycin]. , 1971, Bulletin de la Societe chimique de France.
[90] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.
[91] Hinrich W. H. Göhlmann,et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.
[92] Vadim Makarov,et al. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. , 2010, Journal of the American Chemical Society.
[93] R. Copeland,et al. Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.
[94] Richard E. Lee,et al. Advances in Drug Discovery and Development for Pediatric Tuberculosis. , 2016, Mini reviews in medicinal chemistry.
[95] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[96] I. Morrissey,et al. The MUT056399 Inhibitor of FabI Is a New Antistaphylococcal Compound , 2011, Antimicrobial Agents and Chemotherapy.
[97] Robert H Bates,et al. Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection , 2013, PloS one.
[98] Marianne Terrot,et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. , 2003, Journal of combinatorial chemistry.
[99] Y. Pang,et al. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates , 2015, Antimicrobial Agents and Chemotherapy.
[100] J. Berger,et al. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. , 1991, Chest.
[101] G. Besra,et al. Synthesis of the Arabinose Donor .beta.-D-Arabinofuranosyl-1-monophosphoryldecaprenol, Development of a Basic Arabinosyl-Transferase Assay, and Identification of Ethambutol as an Arabinosyl Transferase Inhibitor , 1995 .
[102] Camilla Rodrigues,et al. Totally drug-resistant tuberculosis in India. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[103] Mikko Niemi,et al. Pharmacokinetic Interactions with Rifampicin , 2003, Clinical pharmacokinetics.
[104] H. Anger,et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. , 2010, The Journal of antimicrobial chemotherapy.
[105] D. Follmann,et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.
[106] N. Vishvanathan,et al. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. , 1991, Diagnostic microbiology and infectious disease.
[107] Shahul Hameed,et al. Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. , 2013, Journal of medicinal chemistry.
[108] Alimuddin Zumla,et al. Advances in the development of new tuberculosis drugs and treatment regimens , 2013, Nature Reviews Drug Discovery.
[109] Tanya Parish,et al. Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. , 2004, Tuberculosis.
[110] Timothy D McHugh,et al. The complex evolution of antibiotic resistance in Mycobacterium tuberculosis. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[111] Wei Li,et al. Novel Insights into the Mechanism of Inhibition of MmpL3, a Target of Multiple Pharmacophores in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.
[112] G. Blandino,et al. Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates. , 2003, The Journal of antimicrobial chemotherapy.
[113] P. Tonge,et al. Drug-target residence time: critical information for lead optimization. , 2010, Current opinion in chemical biology.
[114] Vladimir Romanov,et al. Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor , 2012, Antimicrobial Agents and Chemotherapy.
[115] Brendan Prideaux,et al. Mass spectrometry imaging for drug distribution studies. , 2012, Journal of proteomics.
[116] K. Mdluli,et al. The tuberculosis drug discovery and development pipeline and emerging drug targets. , 2015, Cold Spring Harbor perspectives in medicine.
[117] Nicola J. Ryan,et al. Delamanid: First Global Approval , 2014, Drugs.
[118] Ebert Rh,et al. Distribution and excretion of radioactive isoniazid in tuberculous patients. , 1953 .
[119] P. Tulkens,et al. Influence of Efflux Transporters on the Accumulation and Efflux of Four Quinolones (Ciprofloxacin, Levofloxacin, Garenoxacin, and Moxifloxacin) in J774 Macrophages , 2005, Antimicrobial Agents and Chemotherapy.
[120] C. D. Long,et al. The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis , 2006, Science.
[121] Gavin Churchyard,et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.
[122] D. Schnappinger,et al. Construction of conditional knockdown mutants in mycobacteria. , 2015, Methods in molecular biology.
[123] Matthew D. Zimmerman,et al. The association between sterilizing activity and drug distribution into tuberculosis lesions , 2015, Nature Medicine.
[124] F. Drobniewski. Is death inevitable with multiresistant TB plus HIV infection? , 1997, The Lancet.
[125] David Barros,et al. Rapid Cytolysis of Mycobacterium tuberculosis by Faropenem, an Orally Bioavailable β-Lactam Antibiotic , 2014, Antimicrobial Agents and Chemotherapy.
[126] M. Lipman,et al. Tuberculosis and HIV Co-Infection , 2012, Drugs.
[127] Jon Cohen,et al. Infectious disease. Approval of novel TB drug celebrated--with restraint. , 2013, Science.
[128] C. Nacy,et al. Activity of SQ641, a Capuramycin Analog, in a Murine Model of Tuberculosis , 2009, Antimicrobial Agents and Chemotherapy.
[129] E. J. North,et al. The structure-activity relationship of urea derivatives as anti-tuberculosis agents. , 2011, Bioorganic & medicinal chemistry.
[130] Ruedi Aebersold,et al. The Mtb proteome library: a resource of assays to quantify the complete proteome of Mycobacterium tuberculosis. , 2013, Cell host & microbe.
[131] U. Hallbauer,et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[132] K. Andries,et al. Impact of the Interaction of R207910 with Rifampin on the Treatment of Tuberculosis Studied in the Mouse Model , 2008, Antimicrobial Agents and Chemotherapy.